-

11:09:46 PM

NRXP Stock News

NRXP - NRX Pharmaceuticals Inc

08/23/21 9:33 AM

Nasdaq : NRXP

covid-19

Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, biopharmaceutical company noted today reports 1 in the Israeli media that participants in the BriLife vaccine trial who received the highest dose vaccine were notified by local health authorities

RHEA-AI

neutral

08/19/21 9:18 AM

Nasdaq : NRXP

NRx Pharmaceuticals Announces $30 Million Private Placement

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with investors to purchase 2,727,273 shares of common stock in a private placement. The Company will also

RHEA-AI

neutral

08/18/21 11:53 AM

Nasdaq : NRXP

covid-19

NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19

NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI ™ (aviptadil) which is being tested in the ACTIV-3 Critical Care Phase 3 study sponsored by the National Institutes of Health.

RHEA-AI

neutral

08/16/21 9:32 PM

Nasdaq : NRXP

NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conference call Tuesday, August 17, 2021, at 8:30AM Eastern

RHEA-AI

neutral

08/11/21 4:20 PM

Nasdaq : NRXP

conferences

NRx Pharmaceuticals to Report Second Quarter 2021 Results August 16, 2021

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company, today announced that management will report second quarter 2021 financial results after the

RHEA-AI

neutral

08/10/21 6:48 AM

Nasdaq : NRXP

NRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced that the NRx Team, together with Prof Jonathan Javitt, Founder, Chairman and CEO of NRx, will ring the Nasdaq Closing Bell on Tuesday, August 10,

RHEA-AI

positive

08/09/21 1:13 PM

Nasdaq : NRXP

clinical trialcovid-19

NRx Pharmaceuticals Announces Initiation of Phase 2b Trial of BriLife™ Vaccine for Covid-19 in Nation of Georgia

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced it is initiating a phase 2b dose-confirmatory trial of the BriLife™ vaccine against COVID-19 in the Nation of Georgia. The vaccine is developed by

RHEA-AI

neutral

08/04/21 6:48 AM

Nasdaq : MNKD, NRXP

MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform

MannKind Corporation (Nasdaq: MNKD) has partnered with NRx Pharmaceuticals (Nasdaq: NRXP) (NRx) to evaluate the feasibility of formulating a dry powder formulation of ZYESAMI ™ (aviptadil), a synthetic form of human Vasoactive Intestinal

RHEA-AI

neutral

08/04/21 6:48 AM

Nasdaq : MNKD, NRXP

NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with MannKind Corporation to develop a dry powder formulation of ZYESAMI ™ (aviptadil), a synthetic form of human Vasoactive Intestinal Peptide (VIP), produced by the body

RHEA-AI

positive

07/27/21 11:34 AM

Nasdaq : NRXP

NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia

NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage, global biopharmaceutical company, today announced that the Nation of Georgia's Prime Minister and Minister of Health have issued an Emergency Use Authorization for intravenous ZYESAMI™ (aviptadil)

RHEA-AI

neutral

Prev 1 2 3 4 5 6 7 Next